Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Invivyd Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and ... Invivyd Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's lead product candidate, ADG20 is developed for the treatment and prevention of coronavirus disease which has demonstrated clinically meaningful results in global Phase 3 clinical trials against multiple variants of concern for the prevention and treatment of COVID-19. Mehr anzeigen
New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA™ (pemivibart) against XEC Centers for Disease Control reports XEC and KP.3.1.1 (previously disclosed...
Q3 2024 PEMGARDA™ (pemivibart) net product revenue of $9.3 million; Invivyd ended Q3 2024 with $106.9 million in cash and cash equivalentsTargets near-term (1H 2025) profitability with existing...
The New England Journal of Medicine (NEJM) Letter to the Editor outlines the novel, rapid immunobridging authorization pathway for PEMGARDA and provides an updated correlate of protection curve...
CANOPY manuscript preprint includes six-month off-drug follow-up period that highlighted strong protection by pemivibart versus placebo in the immunocompetent Cohort B during KP.3 and KP.3.1.1...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.0198 | 4.75847152127 | 0.4161 | 0.4471 | 0.38 | 679235 | 0.42002563 | CS |
| 4 | -0.0841 | -16.1730769231 | 0.52 | 0.59 | 0.38 | 1810519 | 0.45825009 | CS |
| 12 | -0.4853 | -52.6812852801 | 0.9212 | 1.07 | 0.38 | 1128371 | 0.55657678 | CS |
| 26 | -0.7841 | -64.2704918033 | 1.22 | 1.455 | 0.38 | 743985 | 0.71138778 | CS |
| 52 | -4.0441 | -90.2700892857 | 4.48 | 5.195 | 0.38 | 709017 | 1.86960851 | CS |
| 156 | -4.2641 | -90.7255319149 | 4.7 | 5.195 | 0.38 | 589196 | 2.32203448 | CS |
| 260 | -4.2641 | -90.7255319149 | 4.7 | 5.195 | 0.38 | 589196 | 2.32203448 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
